NCT07316829Active, not recruiting
TRAnscriptional Profile of Peripheral Blood Cells in Patient With Chronic Kidney and Lung Rejection: Correlation With Response to Extracorporeal Photo-aphereSiS
TRAnscriptional Profile of Peripheral Blood Cells in Patient With Chronic Kidney and Lung Rejection: Correlation With Response to Extracorporeal Photo-aphereSiS: : Studio Osservazionale-ambispettico.
Source: ClinicalTrials.gov · Last updated 5 Jan 2026
Brief summary (registry, in English)
With this project, the research team aims to identify the molecular pathways associated with the response to extracorporeal photonchemioapheresis (ECP) in kidney or lung transplant patients suffering from chronic rejection, by analyzing gene expression in samples of peripheral blood mononuclear cells.
- Status (registry)
- Active, not recruiting
- Study type
- Observational
- Enrollment
- 30 (estimated)
- First submitted
- 19 Dec 2025
- Start date
- 10 Apr 2025
- Primary completion date
- 10 Apr 2026
- Lead sponsor
- Fondazione IRCCS Policlinico San Matteo di Pavia
- NCT number
- NCT07316829
What you commit to
- Study type: Observational
- Planned participants: 30
- From 10 Apr 2025 to the primary completion date, 10 Apr 2026
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Patients will be followed longitudinally for clinical outcomes, donor-specific antibodies, and gene expression profiling at baseline, 6 months, and 12 months.
Other illness
- Active infection or uncontrolled comorbidities that contraindicate ECP
Other
- Pregnancy or breastfeeding
- Participation in another interventional trial that could interfere with outcomes
- Inability to comply with study procedures
- Additional Notes:
- Both prevalent and incident cases may be included (ambispective design).
Who the study is looking for
- Age ≥ 18 years
- Kidney transplant recipients with biopsy-proven AMCR
- Lung transplant recipients with CLAD, defined as a persistent decline in FEV1 ≥ 20% compared with post-transplant baseline in the absence of other causes
- Patients receiving standard immunosuppressive therapy and eligible for Extracorporeal Photoapheresis (ECP)
- Ability to provide informed consent
Age in the registry: 18 years to - · Sex: All
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Fondazione IRCCS Policlinico San Matteo di Pavia Coordinator of this site? Confirm its status | Pavia | Italy | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.